These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 24927849)

  • 21. Cutting edge: FcγRIII (CD16) and FcγRI (CD64) are responsible for anti-glycoprotein 75 monoclonal antibody TA99 therapy for experimental metastatic B16 melanoma.
    Albanesi M; Mancardi DA; Macdonald LE; Iannascoli B; Zitvogel L; Murphy AJ; Daëron M; Leusen JH; Bruhns P
    J Immunol; 2012 Dec; 189(12):5513-7. PubMed ID: 23150715
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets.
    Clynes RA; Towers TL; Presta LG; Ravetch JV
    Nat Med; 2000 Apr; 6(4):443-6. PubMed ID: 10742152
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An Agonistic Anti-CD137 Antibody Disrupts Lymphoid Follicle Structure and T-Cell-Dependent Antibody Responses.
    Hong JP; Reynoso GV; Andhey PS; Swain A; Turner JS; Boon ACM; Krammer F; Ellebedy AH; Zanini F; Artyomov M; Hickman HD; Diamond MS
    Cell Rep Med; 2020 Jun; 1(3):. PubMed ID: 32699843
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-Tumor Necrosis Factor With a Glyco-Engineered Fc-Region Has Increased Efficacy in Mice With Colitis.
    Bloemendaal FM; Levin AD; Wildenberg ME; Koelink PJ; McRae BL; Salfeld J; Lum J; van der Neut Kolfschoten M; Claassens JW; Visser R; Bentlage A; D'Haens GRAM; Verbeek JS; Vidarsson G; van den Brink GR
    Gastroenterology; 2017 Nov; 153(5):1351-1362.e4. PubMed ID: 28756234
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibitory Fcγ receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies.
    Li F; Ravetch JV
    Science; 2011 Aug; 333(6045):1030-4. PubMed ID: 21852502
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antitumor efficacy of CD137 ligation is maximized by the use of a CD137 single-chain Fv-expressing whole-cell tumor vaccine compared with CD137-specific monoclonal antibody infusion.
    Zhang H; Knutson KL; Hellstrom KE; Disis ML; Hellstrom I
    Mol Cancer Ther; 2006 Jan; 5(1):149-55. PubMed ID: 16432173
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The immunotherapy potential of agonistic anti-CD137 (4-1BB) monoclonal antibodies for malignancies and chronic viral diseases].
    Alfaro C; Murillo O; Tirapu I; Azpilicueta A; Huarte E; Arina A; Arribillaga L; Pérez-Gracia JL; Bendandi M; Prieto J; Lasarte JJ; Melero I
    An Sist Sanit Navar; 2006; 29(1):77-96. PubMed ID: 16670731
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic vaccination with tumor cells that engage CD137.
    Hellstrom KE; Hellstrom I
    J Mol Med (Berl); 2003 Feb; 81(2):71-86. PubMed ID: 12601523
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased Carotid Artery Lesion Inflammation Upon Treatment With the CD137 Agonistic Antibody 2A.
    Söderström LÅ; Jin H; Caravaca AS; Klement ML; Li Y; Gisterå A; Hedin U; Maegdefessel L; Hansson GK; Olofsson PS
    Circ J; 2017 Nov; 81(12):1945-1952. PubMed ID: 28747613
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.
    Stavenhagen JB; Gorlatov S; Tuaillon N; Rankin CT; Li H; Burke S; Huang L; Vijh S; Johnson S; Bonvini E; Koenig S
    Cancer Res; 2007 Sep; 67(18):8882-90. PubMed ID: 17875730
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Unique monoclonal antibodies define expression of Fc gamma RI on macrophages and mast cell lines and demonstrate heterogeneity among subcutaneous and other dendritic cells.
    Tan PS; Gavin AL; Barnes N; Sears DW; Vremec D; Shortman K; Amigorena S; Mottram PL; Hogarth PM
    J Immunol; 2003 Mar; 170(5):2549-56. PubMed ID: 12594281
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD137 (4-1BB) stimulation leads to metabolic and functional reprogramming of human monocytes/macrophages enhancing their tumoricidal activity.
    Stoll A; Bruns H; Fuchs M; Völkl S; Nimmerjahn F; Kunz M; Peipp M; Mackensen A; Mougiakakos D
    Leukemia; 2021 Dec; 35(12):3482-3496. PubMed ID: 34021248
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimulation.
    French RR; Taraban VY; Crowther GR; Rowley TF; Gray JC; Johnson PW; Tutt AL; Al-Shamkhani A; Glennie MJ
    Blood; 2007 Jun; 109(11):4810-5. PubMed ID: 17311995
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-CD137 antibodies in the treatment of autoimmune disease and cancer.
    Mittler RS; Foell J; McCausland M; Strahotin S; Niu L; Bapat A; Hewes LB
    Immunol Res; 2004; 29(1-3):197-208. PubMed ID: 15181282
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ.
    Dubrot J; Milheiro F; Alfaro C; Palazón A; Martinez-Forero I; Perez-Gracia JL; Morales-Kastresana A; Romero-Trevejo JL; Ochoa MC; Hervás-Stubbs S; Prieto J; Jure-Kunkel M; Chen L; Melero I
    Cancer Immunol Immunother; 2010 Aug; 59(8):1223-33. PubMed ID: 20336294
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human and mouse CD137 have predominantly different binding CRDs to their respective ligands.
    Yi L; Zhao Y; Wang X; Dai M; Hellström KE; Hellström I; Zhang H
    PLoS One; 2014; 9(1):e86337. PubMed ID: 24466035
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer.
    Guo Z; Cheng D; Xia Z; Luan M; Wu L; Wang G; Zhang S
    J Transl Med; 2013 Sep; 11():215. PubMed ID: 24044888
    [TBL] [Abstract][Full Text] [Related]  

  • 38. T cell costimulation with anti-CD137 monoclonal antibodies is mediated by K63-polyubiquitin-dependent signals from endosomes.
    Martinez-Forero I; Azpilikueta A; Bolaños-Mateo E; Nistal-Villan E; Palazon A; Teijeira A; Perez-Chacon G; Morales-Kastresana A; Murillo O; Jure-Kunkel M; Zapata JM; Melero I
    J Immunol; 2013 Jun; 190(12):6694-706. PubMed ID: 23690480
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CD137 agonist antibody prevents cancer recurrence: contribution of CD137 on both hematopoietic and nonhematopoietic cells.
    Narazaki H; Zhu Y; Luo L; Zhu G; Chen L
    Blood; 2010 Mar; 115(10):1941-8. PubMed ID: 20068221
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Short-term cultured tumor fragments to study immunotherapy combinations based on CD137 (4-1BB) agonism.
    Eguren-Santamaría I; Rodríguez I; Herrero-Martin C; Fernández de Piérola E; Azpilikueta A; Sánchez-Gregorio S; Bolaños E; Gomis G; Molero-Glez P; Chacón E; Mínguez JÁ; Chiva S; Diez-Caballero F; de Andrea C; Teijeira Á; Sanmamed MF; Melero I
    Oncoimmunology; 2024; 13(1):2373519. PubMed ID: 38988823
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.